Showing 211-220 of 377 results for "".
- Dr. Ashley Brissette Is Clinique’s First Guiding Ophthalmologisthttps://modernaesthetics.com/news/nyc-ophthalmologist-dr-ashley-brissette-is-cliniques-first-guiding-ophthalmologist/2473481/NYC-based ophthalmologist Ashley Brissette, MD, MSc, FRCSC, is Clinique’s first guiding ophthalmologist. In the newly created role, Dr. Brissette will help educate consumers on the importance of eye safety, help guide the development of new products, and contribute to C
- Delnova Demonstrates Proof of Concept for ReViVoxhttps://modernaesthetics.com/news/delnova-demonstrates-proof-of-concept-for-revivox/2473478/Delnova’s ReViVox showed reversal or muscle paralysis or weakness in a small cohort of healthy subjects. ReViVox is being developed to resolve side effects that may result from botulinum neurotoxin treatments. In the proof-of-concept study, volunteer subj
- PDO Max Launches Molded Levo Max Threadshttps://modernaesthetics.com/news/pdo-max-launches-molded-levo-max-threads/2473472/PDO MAX is introducing Molded Levo Max, bi-directional and barbed threads that are engineered for contouring the lower face, jawline, and general submentum area. PDO Max's Molded Levo Max threads grab submental fat and reposition it along the natural contours created
- Meet the Beauty Health Company’s New CFO: Michael Monahanhttps://modernaesthetics.com/news/meet-the-beauty-health-companys-new-ceo-michael-monahan/2473471/Michael Monahan is The Beauty Health Company’s new Chief Financial Officer, effective August 10, 2023. He succeeds Liyuan Woo, who is leaving BeautyHealth but will remain as an advisor until September 1, 2023 to assist with the transition. "Michael
- Evolus Unveils New Branding for Jeuveauhttps://modernaesthetics.com/news/evolus-unveils-new-branding-for-jeuveau/2473470/Evolus, Inc. is unveiling its new branding for Jeuveau (prabotulinumtoxinA-xvfs). The new Jeuveau imagery reflects today’s consumers, many of whom are millennials and younger. The “Jeuveau, You See Me” marketing campaign uses inclusive messaging to encourage
- Nulastin Taps Felipe Jimenez, PhD, for Chief Science Officerhttps://modernaesthetics.com/news/nulastin-taps-felipe-jimenez-phd-for-chief-science-officer/2473462/Felipe Jimenez, PhD, is Nulastin’s new Chief Science Officer. Formerly of Benchmark Cosmetic Laboratories (a KDC/One company) and Guthy-Renker, Mr. Jimenez holds more than 30 patents on elastin regeneration. "This is a dream come true having F
- EWG Survey: Men’s Use of Personal Care Products Doubles Since 2004https://modernaesthetics.com/news/ewg-survey-mens-use-of-personal-care-products-doubles-since-2004/2473459/Men’s use of personal care products has doubled since 2004, according to new consumer survey commissioned by the Environmental Working Group. Specifically, the average adult man in the U.S. uses 11 different personal care products each day – nearly twice as ma
- L'Oréal CEO to Deliver Keynote at CES 2024https://modernaesthetics.com/news/loreal-ceo-to-deliver-keynote-at-ces-2024/2473457/L'Oréal CEO Nicolas Hieronimus will deliver the first-ever keynote from a beauty company at CES 2024. L'Oréal's keynote will showcase the role that sustainable, accessible and inclusive beauty tech plays in driving positive impact at an individu
- SK-II Introduces Pitera Expert Panelhttps://modernaesthetics.com/news/sk-ii-introduces-pitera-expert-panel/2473450/SK-II’s PITERA may reduce the Aging Trigger Factor (AT-0), potentially slowing skin aging, according to research presented at the World Congress of Dermatology 2023 in Singapore. AT-0 accelerates signs of aging via a chain reaction, even as early as i
- Venus Concept Introduces Medical Advisory Board for AI.MEhttps://modernaesthetics.com/news/venus-concept-introduces-medical-advisory-board-for-aime/2473449/The primary mission of the medical advisory board will be to provide strategic input, guidance, and clinical recommendations regarding the Company's emerging robotic technology, AI.ME, which received its first 510(k) clearance from the U.S. Food and Drug Administration (FDA) in December 2022,